ASCO 2021 | CheckRad-CD8: checkpoint blockade + RT dependent on intratumoral CD8+ T-cell infiltration in HNSCC
Markus Hecht, MD, PhD, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany, discusses the primary results of the CheckRad-CD8 trial (NCT03426657), a Phase II study evaluating first-line double checkpoint blockade with durvalumab and tremelimumab and radiotherapy (RT) dependent on intratumoral CD8+ T-cell infiltration in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) under the rationale that targeting CTLA-4, an immune checkpoint, may result in synergistic effects with radiotherapy. CheckRad-DC8 met ints primary feasibility endpoint and CD8+ T-cell-based pathological patient selection resulted in promising progression-free survival in patients with locally advanced HNSCC. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Markus Hecht, MD, PhD, has received an advisory role, speakers’ bureau, honoraria, travel expenses, and research funding from Merck Serono, MSD and BMS, research funding from AstraZeneca and Novartis, as well as travel expenses from Teva.
